QQQ   337.27 (+1.86%)
AAPL   175.05 (+1.37%)
MSFT   318.52 (+1.44%)
META   246.85 (+1.80%)
GOOGL   122.83 (+1.65%)
AMZN   118.15 (+2.29%)
TSLA   176.89 (+1.74%)
NVDA   316.78 (+4.97%)
NIO   7.82 (-2.62%)
BABA   85.77 (-5.41%)
AMD   107.93 (+4.03%)
T   16.55 (-0.66%)
F   11.64 (+1.22%)
MU   67.57 (+4.08%)
CGC   1.05 (+0.00%)
GE   104.01 (+0.52%)
DIS   93.76 (+1.07%)
AMC   5.07 (-0.59%)
PFE   36.48 (-0.73%)
PYPL   61.27 (-0.31%)
NFLX   371.29 (+9.22%)
QQQ   337.27 (+1.86%)
AAPL   175.05 (+1.37%)
MSFT   318.52 (+1.44%)
META   246.85 (+1.80%)
GOOGL   122.83 (+1.65%)
AMZN   118.15 (+2.29%)
TSLA   176.89 (+1.74%)
NVDA   316.78 (+4.97%)
NIO   7.82 (-2.62%)
BABA   85.77 (-5.41%)
AMD   107.93 (+4.03%)
T   16.55 (-0.66%)
F   11.64 (+1.22%)
MU   67.57 (+4.08%)
CGC   1.05 (+0.00%)
GE   104.01 (+0.52%)
DIS   93.76 (+1.07%)
AMC   5.07 (-0.59%)
PFE   36.48 (-0.73%)
PYPL   61.27 (-0.31%)
NFLX   371.29 (+9.22%)
QQQ   337.27 (+1.86%)
AAPL   175.05 (+1.37%)
MSFT   318.52 (+1.44%)
META   246.85 (+1.80%)
GOOGL   122.83 (+1.65%)
AMZN   118.15 (+2.29%)
TSLA   176.89 (+1.74%)
NVDA   316.78 (+4.97%)
NIO   7.82 (-2.62%)
BABA   85.77 (-5.41%)
AMD   107.93 (+4.03%)
T   16.55 (-0.66%)
F   11.64 (+1.22%)
MU   67.57 (+4.08%)
CGC   1.05 (+0.00%)
GE   104.01 (+0.52%)
DIS   93.76 (+1.07%)
AMC   5.07 (-0.59%)
PFE   36.48 (-0.73%)
PYPL   61.27 (-0.31%)
NFLX   371.29 (+9.22%)
QQQ   337.27 (+1.86%)
AAPL   175.05 (+1.37%)
MSFT   318.52 (+1.44%)
META   246.85 (+1.80%)
GOOGL   122.83 (+1.65%)
AMZN   118.15 (+2.29%)
TSLA   176.89 (+1.74%)
NVDA   316.78 (+4.97%)
NIO   7.82 (-2.62%)
BABA   85.77 (-5.41%)
AMD   107.93 (+4.03%)
T   16.55 (-0.66%)
F   11.64 (+1.22%)
MU   67.57 (+4.08%)
CGC   1.05 (+0.00%)
GE   104.01 (+0.52%)
DIS   93.76 (+1.07%)
AMC   5.07 (-0.59%)
PFE   36.48 (-0.73%)
PYPL   61.27 (-0.31%)
NFLX   371.29 (+9.22%)

Brookline Capital Management Analyst Recommendations & Stock Picks

This page lists the most recent publicly-reported stock recommendations and ratings issued by analysts at Brookline Capital Management. These ratings and price targets were collected from public media reports and are believed to be accurate, but cannot be verified with 100% certainty. MarketBeat and its parent company are in no way affiliated with or endorsed by Brookline Capital Management.

MarketRank evaluates a company based on community opinion, dividend strength, institutional and insider ownership, earnings and valuation, and analysts forecasts.
Available with a MarketBeat All Access Subscription
MarketRank™Upgrade to All Access to use the All Ranks Filter
Media sentiment refers to the percentage of positive news stories versus negative news stories a company has received in the past week.
Available with a MarketBeat All Access Subscription
Media SentimentUpgrade to All Access to use the All Sentiments Filter
Analyst consensus is the average investment recommendation among Wall Street research analysts.
Available with a MarketBeat All Access Subscription
Analyst ConsensusUpgrade to All Access to use the All Ratings Filter
CompanyDateActionBrokerageAnalystRatingPrice TargetImpact on PriceDetailsActions
Oncternal Therapeutics stock logo
ONCT
Oncternal Therapeutics
4/3/2023Downgraded byBrookline Capital ManagementAnalyst K. DolliverBuy -> HoldLow
9 Meters Biopharma stock logo
NMTR
9 Meters Biopharma
3/22/2023Reiterated byBrookline Capital ManagementAnalyst K. DolliverBuyLow
Apexigen stock logo
APGN
Apexigen
3/10/2023Downgraded byBrookline Capital ManagementAnalyst K. DolliverBuy -> HoldLow
Oncternal Therapeutics stock logo
ONCT
Oncternal Therapeutics
3/9/2023Reiterated byBrookline Capital ManagementAnalyst K. DolliverBuyLow
Daré Bioscience stock logo
DARE
Daré Bioscience
2/14/2023Reiterated byBrookline Capital ManagementAnalyst K. DolliverBuyLow
Fusion Pharmaceuticals stock logo
FUSN
Fusion Pharmaceuticals
2/13/2023Reiterated byBrookline Capital ManagementAnalyst K. DolliverBuyLow
Hepion Pharmaceuticals stock logo
HEPA
Hepion Pharmaceuticals
1/31/2023Reiterated byBrookline Capital ManagementAnalyst K. DolliverBuyLow
Atreca stock logo
BCEL
Atreca
1/20/2023Reiterated byBrookline Capital ManagementAnalyst K. DolliverBuyLow
electroCore stock logo
ECOR
electroCore
1/12/2023Reiterated byBrookline Capital ManagementAnalyst K. DolliverBuyN/A
Biocept stock logo
BIOC
Biocept
1/6/2023Downgraded byBrookline Capital ManagementAnalyst K. DolliverBuy -> HoldLow
Apexigen stock logo
APGN
Apexigen
12/12/2022Reiterated byBrookline Capital ManagementAnalyst K. DolliverBuyLow
Imunon stock logo
IMNN
Imunon
11/14/2022Reiterated byBrookline Capital ManagementAnalyst K. DolliverBuyLow
9 Meters Biopharma stock logo
NMTR
9 Meters Biopharma
10/25/2022Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyLow
Vaxart stock logo
VXRT
Vaxart
10/3/2022Reiterated byBrookline Capital ManagementAnalyst K. DolliverBuyLow
Outlook Therapeutics stock logo
OTLK
Outlook Therapeutics
10/3/2022Reiterated byBrookline Capital ManagementAnalyst K. DolliverBuyLow
9 Meters Biopharma stock logo
NMTR
9 Meters Biopharma
10/3/2022Reiterated byBrookline Capital ManagementAnalyst K. DolliverBuyLow
Monopar Therapeutics stock logo
MNPR
Monopar Therapeutics
10/3/2022Reiterated byBrookline Capital ManagementAnalyst K. DolliverBuyLow
Lisata Therapeutics stock logo
LSTA
Lisata Therapeutics
10/3/2022Reiterated byBrookline Capital ManagementAnalyst K. DolliverBuyLow
Imunon stock logo
IMNN
Imunon
10/3/2022Reiterated byBrookline Capital ManagementAnalyst K. DolliverBuyLow
Edesa Biotech stock logo
EDSA
Edesa Biotech
10/3/2022Reiterated byBrookline Capital ManagementAnalyst K. DolliverBuyLow
Biocept stock logo
BIOC
Biocept
10/3/2022Reiterated byBrookline Capital ManagementAnalyst K. DolliverBuyLow
Antibe Therapeutics stock logo
ATE
Antibe Therapeutics
8/15/2022Reiterated byBrookline Capital ManagementAnalyst K. DolliverBuyN/A
Arcturus Therapeutics stock logo
ARCT
Arcturus Therapeutics
8/10/2022Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyLow
Atreca stock logo
BCEL
Atreca
8/8/2022Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyLow
Antibe Therapeutics stock logo
ATBPF
Antibe Therapeutics
6/30/2022Reiterated byBrookline Capital ManagementAnalyst K. DolliverBuyN/A
Veru stock logo
VERU
Veru
5/18/2022Target Raised byBrookline Capital ManagementAnalyst Kumaraguru RajaBuy -> Buy$29.00 -> $31.00Medium
Bellerophon Therapeutics stock logo
BLPH
Bellerophon Therapeutics
4/4/2022Target Lowered byBrookline Capital Management$26.00 -> $19.00Low
Verrica Pharmaceuticals stock logo
VRCA
Verrica Pharmaceuticals
3/10/2022Reiterated byBrookline Capital ManagementAnalyst K. DolliverBuyMedium
Intellia Therapeutics stock logo
NTLA
Intellia Therapeutics
3/7/2022Upgraded byBrookline Capital ManagementAnalyst L. CannHold -> Buy $91.00High
CTI BioPharma stock logo
CTIC
CTI BioPharma
3/1/2022Target Raised byBrookline Capital ManagementAnalyst L. CannBuy -> Buy$7.20 -> $12.00High
CRISPR Therapeutics stock logo
CRSP
CRISPR Therapeutics
2/14/2022Reiterated byBrookline Capital ManagementAnalyst Leah RushBuy $143.00High
Intellia Therapeutics stock logo
NTLA
Intellia Therapeutics
2/14/2022Reiterated byBrookline Capital ManagementAnalyst Leah RushBuyLow
Caribou Biosciences stock logo
CRBU
Caribou Biosciences
2/14/2022Reiterated byBrookline Capital ManagementAnalyst L. CannBuyMedium
BioCardia stock logo
BCDA
BioCardia
2/3/2022Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyHigh
Fusion Pharmaceuticals stock logo
FUSN
Fusion Pharmaceuticals
2/2/2022Reiterated byBrookline Capital ManagementAnalyst K. DolliverBuyMedium
IceCure Medical stock logo
ICCM
IceCure Medical
2/1/2022Reiterated byBrookline Capital ManagementAnalyst K. DolliverBuyLow
Hepion Pharmaceuticals stock logo
HEPA
Hepion Pharmaceuticals
1/26/2022Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyLow
Daré Bioscience stock logo
DARE
Daré Bioscience
1/19/2022Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyHigh
Procaps Group stock logo
PROC
Procaps Group
12/14/2021Reiterated byBrookline Capital ManagementAnalyst Kemp DolliverBuy $13.00Low
POINT Biopharma Global stock logo
PNT
POINT Biopharma Global
12/1/2021Reiterated byBrookline Capital ManagementAnalyst Kemp DolliverBuy $23.00Medium
CTI BioPharma stock logo
CTIC
CTI BioPharma
11/15/2021Reiterated byBrookline Capital ManagementAnalyst L. CannBuyHigh
Novan stock logo
NOVN
Novan
10/19/2021Reiterated byBrookline Capital ManagementAnalyst Kemp DolliverBuy $16.00Medium
Kymera Therapeutics stock logo
KYMR
Kymera Therapeutics
10/13/2021Reiterated byBrookline Capital ManagementAnalyst Leah Rush CannBuy $80.00Medium
Biocept stock logo
BIOC
Biocept
10/8/2021Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyMedium
Forte Biosciences stock logo
FBRX
Forte Biosciences
9/3/2021Reiterated byBrookline Capital ManagementAnalyst K. RajaHoldLow
Veru stock logo
VERU
Veru
8/27/2021Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyMedium
SCYNEXIS stock logo
SCYX
SCYNEXIS
8/24/2021Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyLow
Atreca stock logo
BCEL
Atreca
7/29/2021Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyHigh
C4 Therapeutics stock logo
CCCC
C4 Therapeutics
6/25/2021Reiterated byBrookline Capital ManagementAnalyst Leah Rush CannBuyHigh
Bellerophon Therapeutics stock logo
BLPH
Bellerophon Therapeutics
6/23/2021Reiterated byBrookline Capital ManagementAnalyst K. DolliverBuyMedium
Antibe Therapeutics stock logo
ATE
Antibe Therapeutics
6/3/2021Reiterated byBrookline Capital ManagementAnalyst K. DolliverBuyN/A
Antibe Therapeutics stock logo
ATBPF
Antibe Therapeutics
6/3/2021Reiterated byBrookline Capital ManagementAnalyst K. DolliverBuyMedium
Monopar Therapeutics stock logo
MNPR
Monopar Therapeutics
5/25/2021Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyMedium
Bioceres Crop Solutions stock logo
BIOX
Bioceres Crop Solutions
5/7/2021Reiterated byBrookline Capital ManagementAnalyst K. DolliverBuyN/A
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
3/30/2021Reiterated byBrookline Capital ManagementAnalyst L. CannBuyN/A
Oncternal Therapeutics stock logo
ONCT
Oncternal Therapeutics
3/30/2021Reiterated byBrookline Capital ManagementAnalyst K. RajaBuy $16.00High
9 Meters Biopharma stock logo
NMTR
9 Meters Biopharma
3/25/2021Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyHigh
Moderna stock logo
MRNA
Moderna
2/26/2021Target Raised byBrookline Capital ManagementBuy$180.00 -> $205.00Low
X4 Pharmaceuticals stock logo
XFOR
X4 Pharmaceuticals
12/17/2020Initiated byBrookline Capital ManagementAnalyst L. CannBuy $21.00High
Veru stock logo
VERU
Veru
12/14/2020Target Raised byBrookline Capital ManagementAnalyst K. Raja$13.00 -> $17.00High
Syros Pharmaceuticals stock logo
SYRS
Syros Pharmaceuticals
11/10/2020Initiated byBrookline Capital ManagementAnalyst L. CannBuy $190.00Low
CTI BioPharma stock logo
CTIC
CTI BioPharma
10/23/2020Initiated byBrookline Capital ManagementAnalyst L. CannBuy $7.00Medium
electroCore stock logo
ECOR
electroCore
10/23/2020Initiated byBrookline Capital ManagementAnalyst S. YanchusBuy $75.00Low
Aspira Women's Health stock logo
AWH
Aspira Women's Health
10/14/2020Reiterated byBrookline Capital ManagementAnalyst S. YanchusBuyHigh
Aspira Women's Health stock logo
AWH
Aspira Women's Health
10/14/2020Reiterated byBrookline Capital ManagementAnalyst S. YanchusBuyHigh
MEI Pharma stock logo
MEIP
MEI Pharma
10/12/2020Reiterated byBrookline Capital ManagementAnalyst L. CannBuyMedium
DermTech stock logo
DMTK
DermTech
9/11/2020Initiated byBrookline Capital ManagementAnalyst S. YanchusBuyHigh
Medicenna Therapeutics stock logo
MDNA
Medicenna Therapeutics
8/24/2020Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyMedium
Forte Biosciences stock logo
FBRX
Forte Biosciences
8/28/2020Initiated byBrookline Capital ManagementAnalyst K. RajaBuy $90.00Low
FSD Pharma stock logo
HUGE
FSD Pharma
8/20/2020Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyLow
FSD Pharma stock logo
HUGE
FSD Pharma
8/20/2020Initiated byBrookline Capital ManagementBuy $11.00N/A
Kura Oncology stock logo
KURA
Kura Oncology
8/16/2020Reiterated byBrookline Capital ManagementAnalyst L. CannBuyLow
9 Meters Biopharma stock logo
NMTR
9 Meters Biopharma
8/18/2020Initiated byBrookline Capital ManagementAnalyst S. YanchusBuy $100.00High
Veru stock logo
VERU
Veru
8/14/2020Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyLow
Arcturus Therapeutics stock logo
ARCT
Arcturus Therapeutics
8/11/2020Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyLow
Antibe Therapeutics stock logo
ATE
Antibe Therapeutics
7/15/2020Reiterated byBrookline Capital ManagementAnalyst S. YanchusBuyN/A
Moderna stock logo
MRNA
Moderna
7/13/2020Reiterated byBrookline Capital ManagementAnalyst L. CannBuy $95.00High
Assertio stock logo
ASRT
Assertio
6/3/2020Initiated byBrookline Capital ManagementBuy $3.50Low
Biocept stock logo
BIOC
Biocept
5/14/2020Initiated byBrookline Capital ManagementAnalyst S. YanchusBuyHigh
Outlook Therapeutics stock logo
OTLK
Outlook Therapeutics
5/5/2020Initiated byBrookline Capital ManagementAnalyst K. RajaBuyHigh
Daré Bioscience stock logo
DARE
Daré Bioscience
4/28/2020Initiated byBrookline Capital ManagementAnalyst S. YanchusBuy $7.50High
Bellerophon Therapeutics stock logo
BLPH
Bellerophon Therapeutics
4/14/2020Initiated byBrookline Capital ManagementAnalyst S. YanchusBuy $35.00Low
Edesa Biotech stock logo
EDSA
Edesa Biotech
3/30/2020Initiated byBrookline Capital ManagementAnalyst K. RajaBuy $10.00High
ClearPoint Neuro stock logo
CLPT
ClearPoint Neuro
3/11/2020Reiterated byBrookline Capital ManagementAnalyst S. YanchusBuyHigh
Armata Pharmaceuticals stock logo
ARMP
Armata Pharmaceuticals
3/13/2020Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyHigh
ClearPoint Neuro stock logo
CLPT
ClearPoint Neuro
3/12/2020Initiated byBrookline Capital ManagementBuy $15.00N/A
Monopar Therapeutics stock logo
MNPR
Monopar Therapeutics
2/19/2020Initiated byBrookline Capital ManagementAnalyst K. RajaBuy $42.00High
Bioceres Crop Solutions stock logo
BIOX
Bioceres Crop Solutions
2/4/2020Reiterated byBrookline Capital ManagementAnalyst S. YanchusBuyN/A
BioCardia stock logo
BCDA
BioCardia
11/26/2019Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyLow
BioCardia stock logo
BCDA
BioCardia
11/26/2019Initiated byBrookline Capital ManagementBuy $22.00Low
Medicenna Therapeutics stock logo
MDNA
Medicenna Therapeutics
11/19/2019Reiterated byBrookline Capital ManagementBuy C$4.00N/A
Atreca stock logo
BCEL
Atreca
8/20/2019Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyHigh
SCYNEXIS stock logo
SCYX
SCYNEXIS
8/19/2019Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyHigh
Vaxart stock logo
VXRT
Vaxart
8/15/2019Initiated byBrookline Capital ManagementAnalyst K. RajaBuy $6.00Low
Veru stock logo
VERU
Veru
7/29/2019Initiated byBrookline Capital ManagementAnalyst K. RajaBuy $12.00High
NightHawk Biosciences stock logo
NHWK
NightHawk Biosciences
7/29/2019Initiated byBrookline Capital ManagementAnalyst K. RajaBuy$56.00 -> $56.00High
Cellectar Biosciences stock logo
CLRB
Cellectar Biosciences
7/29/2019Initiated byBrookline Capital ManagementAnalyst K. RajaBuy$60.00 -> $60.00High
Arcturus Therapeutics stock logo
ARCT
Arcturus Therapeutics
7/24/2019Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyHigh
SCYNEXIS stock logo
SCYX
SCYNEXIS
1/4/2019Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyHigh
Cellectar Biosciences stock logo
CLRB
Cellectar Biosciences
11/20/2018Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyLow
Arcturus Therapeutics stock logo
ARCT
Arcturus Therapeutics
9/27/2018Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyLow
NightHawk Biosciences stock logo
NHWK
NightHawk Biosciences
8/1/2018Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyLow
Tonix Pharmaceuticals stock logo
TNXP
Tonix Pharmaceuticals
7/27/2018Downgraded byBrookline Capital ManagementAnalyst K. RajaBuy -> HoldLow
Tonix Pharmaceuticals stock logo
TNXP
Tonix Pharmaceuticals
5/1/2018Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyLow

MarketBeat Community Rating for Brookline Capital Management

Community Ranking:  2.9 out of 5 (
2.9 of 5 stars)
Outperform Votes:  20,204 (Vote Outperform)
Underperform Votes:  14,998 (Vote Underperform)
Total Votes:  35,202
MarketBeat's community ratings are surveys of what our community members think about Brookline Capital Management and other research firms. Vote "Outperform" if you believe Brookline Capital Management's recommendations will outperform the S&P 500 over the long term. Vote "Underperform" if you believe Brookline Capital Management's recommendations will underperform the S&P 500 over the long term. You may vote once every thirty days.

Stock Ratings Reports and Tools

My Account -